09.13.16
Lonza, Basel, Switzerland, has closed the acquisition of InterHealth Nutraceuticals, Benicia, CA, a leader in research, development, manufacture and marketing of proprietary, value-added nutritional ingredients for use in dietary supplements, from Kainos Capital.
The InterHealth business will become part of Lonza’s Consumer Care Business Unit, but will retain its facilities and employees. The combination of the two businesses allows Lonza to offer InterHealth’s more than 15 branded ingredients, including its cornerstone ingredient, UC-II, which is positioned for the joint-health segment.
“We are looking forward to welcoming the highly capable team to our Lonza family. They nicely complement our offerings and will be joining us in our quest to becoming the world’s leading and most-trusted supplier to the pharmaceutical, biotech and specialty ingredients markets.” said Richard Ridinger, Lonza’s CEO. “Lonza will be able to harness the proven management and branding capabilities and leverage them to a global level.”
Lonza acquired InterHealth for a total transaction price of up to $300 million split into an upfront payment and an earn-out payment. The transaction is expected to be immediately accretive to Lonza’s earnings.
The InterHealth business will become part of Lonza’s Consumer Care Business Unit, but will retain its facilities and employees. The combination of the two businesses allows Lonza to offer InterHealth’s more than 15 branded ingredients, including its cornerstone ingredient, UC-II, which is positioned for the joint-health segment.
“We are looking forward to welcoming the highly capable team to our Lonza family. They nicely complement our offerings and will be joining us in our quest to becoming the world’s leading and most-trusted supplier to the pharmaceutical, biotech and specialty ingredients markets.” said Richard Ridinger, Lonza’s CEO. “Lonza will be able to harness the proven management and branding capabilities and leverage them to a global level.”
Lonza acquired InterHealth for a total transaction price of up to $300 million split into an upfront payment and an earn-out payment. The transaction is expected to be immediately accretive to Lonza’s earnings.
